Antonio Franco, Carbognin Luisa, Paris Ida, Di Leone Alba, Orlandi Armando, Marazzi Fabio, Mule Antonino, Belli Paolo, Rossi Alessandro, Magno Stefano, Palazzo Antonella, Masiello Valeria, Santoro Angela, Fuso Paola, Bria Emilio, D'Archi Sabatino, Scardina Lorenzo, Sanchez Alejandro Martin, Giannarelli Diana, Paternello Stefano, Garganese Giorgia, Scambia Giovanni, Tortora Giampaolo, Masetti Riccardo, Franceschini Gianluca, Fabi Alessandra
Breast Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Precision Medicine Unit in Senology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Future Oncol. 2025 Jul;21(17):2215-2223. doi: 10.1080/14796694.2025.2516410. Epub 2025 Jun 14.
Neoadjuvant chemotherapy (NACT) improves oncologic and cosmetic outcomes in breast cancer (BC), yet recurrence remains a concern. This study identifies factors associated with recurrence at 3 and 5 years in BC patients receiving NACT.
A retrospective analysis of 933 stage I - III BC patients (2014-2021) evaluated event-free survival (EFS) predictors using multivariate analyses.
Lower 5-year EFS was linked to axillary staging (cN, < 0.001), molecular subtype ( < 0.001), surgery type ( = 0.030), and post-surgical nodal status (ypN, = 0.005). High recurrence risk was observed with aggressive tumor biology, advanced disease, and residual nodal burden, while favorable responses correlated with better outcomes.
Biological and clinical factors guide post-NACT strategies to reduce recurrence in high-risk BC patients.
新辅助化疗（NACT）可改善乳腺癌（BC）的肿瘤学和美容效果，但复发仍是一个问题。本研究确定了接受NACT的BC患者3年和5年复发的相关因素。
对933例I - III期BC患者（2014 - 2021年）进行回顾性分析，采用多因素分析评估无事件生存期（EFS）预测因素。
5年EFS较低与腋窝分期（cN，<0.001）、分子亚型（<0.001）、手术类型（=0.030）和术后淋巴结状态（ypN，=0.005）有关。侵袭性肿瘤生物学行为、晚期疾病和残留淋巴结负担会导致高复发风险，而良好反应与更好的预后相关。
生物学和临床因素指导NACT后的策略，以降低高危BC患者的复发率。
